CCA
EDIT icon

Catalyst Capital Advisors’s Editas Medicine EDIT Stock Holding History

Catalyst Capital Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-130
Closed -$3K – 465
2016
Q2 		$3K Hold
130
– – ﹤0.01% 365
2016
Q1 		$4K Buy
+130
New +$3.42K ﹤0.01% 426

Other funds holding EDIT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Catalyst Capital Advisors's EDIT Position: Q3 2016 in Review

Catalyst Capital Advisors sold out of Editas Medicine (EDIT) in Q3 2016, closing a stake of 130 shares — an estimated $3K sold.

Catalyst Capital Advisors first reported a position in EDIT in Q1 2016 and held it in 2 quarters. The position peaked at $4K in Q1 2016. 75 funds tracked by Wall St. Rank hold EDIT as of Q3 2016.

  • Catalyst Capital Advisors reported no remaining Editas Medicine position as of Q3 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 130 Editas Medicine shares in Q3 2016, an estimated $3K.
  • Catalyst Capital Advisors first reported a position in Editas Medicine in Q1 2016 and held it in 2 quarters.
  • Catalyst Capital Advisors's Editas Medicine position peaked at $4K in Q1 2016.
  • 75 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2016.

Based on Catalyst Capital Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.